On this page
CHEK2
checkpoint kinase 2
CHEK2 encodes checkpoint kinase 2, a tumour suppressor kinase that halts cell division when DNA damage is detected, allowing time for repair or triggering cell death if damage is irreparable. When DNA sustains damage, cells must choose between repairing the lesion or eliminating themselves to prevent propagation of mutations.
CHEK2 is located on the long (q) arm of chromosome 22, at band 22q12.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 22 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The CHEK2 gene encodes checkpoint kinase 2, a serine/threonine protein kinase that functions as a central coordinator of the cellular DNA damage response. When sensors detect DNA double-strand breaks or replication stress, they activate CHEK2, which then phosphorylates numerous substrate proteins to orchestrate cell cycle arrest, DNA repair pathway activation, and apoptotic programmes. This tumour suppressor activity makes CHEK2 essential for maintaining genomic stability across cell divisions.
Pathogenic variants in CHEK2 are recognised as clinically actionable secondary findings under the American College of Medical Genetics and Genomics recommendations, reflecting the substantial cancer predisposition they confer. Carriers face moderately increased lifetime risk for breast cancer, with evidence also supporting elevated risk for prostate, colorectal, kidney and thyroid malignancies. The gene is located on chromosome 22q12.1 and encodes a 543-amino acid protein organised into distinct functional domains that mediate signal recognition and downstream phosphorylation events. Understanding CHEK2 status enables targeted surveillance strategies and informs clinical management decisions for at-risk individuals.
What the gene does
Checkpoint kinase 2 operates as a signal amplifier and effector kinase within the ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) damage-response pathways. Following detection of DNA double-strand breaks, the ATM kinase phosphorylates CHEK2 at threonine 68, inducing CHEK2 dimerisation and full catalytic activation. Once activated, CHEK2 phosphorylates over 20 documented substrate proteins, translating initial damage signals into coordinated cellular responses.
A primary CHEK2 substrate is the tumour suppressor p53, which CHEK2 phosphorylates at serine 20. This modification stabilises p53 by blocking its interaction with MDM2, an E3 ubiquitin ligase that normally targets p53 for degradation. Stabilised p53 accumulates in the nucleus and activates transcription of genes controlling cell cycle arrest, DNA repair, and apoptosis. Through this mechanism, CHEK2 helps ensure that cells with damaged genomes do not progress through division until repair is complete or, if damage is too extensive, are eliminated.
Beyond p53, CHEK2 phosphorylates CDC25 phosphatases, which normally activate cyclin-dependent kinases that drive cell cycle progression. CHEK2-mediated phosphorylation of CDC25A and CDC25C leads to their degradation or cytoplasmic sequestration, effectively preventing premature entry into S phase or mitosis. CHEK2 also phosphorylates BRCA1, enhancing its recruitment to DNA damage sites and promoting homologous recombination repair of double-strand breaks. Additional substrates include PML, which CHEK2 phosphorylates to promote formation of nuclear bodies involved in DNA repair, and E2F1, a transcription factor whose CHEK2-dependent modification influences apoptotic responses.
The protein's kinase activity depends on proper domain organisation and conformational changes. Following damage-induced phosphorylation, CHEK2 undergoes autophosphorylation at multiple sites within its activation loop, further enhancing catalytic efficiency. This multi-step activation cascade ensures that CHEK2 signalling is tightly regulated and proportional to the severity of genomic insult. The kinase also participates in regulation of homologous recombination, base excision repair, and nucleotide excision repair pathways, demonstrating its broad influence across DNA maintenance systems.
Video: Genetics 101
Chromosome location
The CHEK2 gene resides on the long arm of chromosome 22 at cytogenetic band 22q12.1, a region spanning approximately 54 kilobases of genomic DNA. The gene comprises 14 exons that encode the 543-amino acid checkpoint kinase 2 protein. This chromosomal region contains several other genes involved in cellular regulation and has been the subject of linkage studies for familial cancer predisposition.
The relatively compact genomic structure of CHEK2 means that most coding sequence variants occur within a limited physical span. Exon-intron boundaries are well characterised, facilitating comprehensive sequencing approaches in clinical genetic testing. The gene's location on chromosome 22, one of the smaller human autosomes, places it outside the major cancer-associated gene clusters found on other chromosomes, though neighbouring genes may share regulatory elements that influence CHEK2 expression under certain cellular conditions.
Protein structure
Checkpoint kinase 2 exhibits a modular domain architecture that directly reflects its biochemical function as a signal transduction kinase. The protein begins with an N-terminal disordered region spanning amino acids 1 to 66, which contains the critical threonine 68 residue that serves as the primary ATM phosphorylation site. Phosphorylation of this residue triggers the conformational changes required for CHEK2 activation.
Immediately downstream lies the forkhead-associated (FHA) domain, extending from amino acids 113 to 175. This domain recognises and binds phosphorylated threonine residues on partner proteins, enabling CHEK2 to interact with phosphorylated substrates and adaptor proteins in the damage response network. The FHA domain is essential for CHEK2 dimerisation following activation and for recruitment to sites of DNA damage through interaction with phosphorylated mediator proteins.
The central and largest region is the protein kinase domain, spanning amino acids 220 to 486. This catalytic domain adopts the conserved kinase fold and contains the ATP-binding pocket and substrate-binding groove necessary for phosphotransferase activity. Embedded within this domain is the T-loop or activation segment, which extends from amino acids 368 to 394 and contains multiple autophosphorylation sites. Phosphorylation of these sites stabilises the kinase in its active conformation, enhancing catalytic turnover and ensuring sustained signalling after initial activation.
The protein concludes with a second disordered region from amino acids 506 to 538 at the C-terminus. Disordered regions often serve as sites for regulatory post-translational modifications and protein-protein interactions, and the C-terminal tail of CHEK2 likely contributes to substrate recognition and subcellular localisation. The combination of structured catalytic and recognition domains with flexible regulatory regions allows CHEK2 to integrate multiple signals and coordinate diverse downstream responses to genomic stress.
Key variants
The variant landscape of CHEK2 includes both truncating alterations and missense changes that disrupt protein function through distinct molecular mechanisms. Protein-truncating variants, including frameshift, nonsense and splice-site alterations, typically result in complete loss of kinase activity either through production of unstable truncated proteins or triggering of nonsense-mediated decay. One extensively characterised example is the c.1100delC frameshift variant, which occurs in approximately 1% of Northern and Eastern European populations and is classified as pathogenic based on robust segregation and case-control data.
Missense variants present a more heterogeneous picture, with pathogenicity depending on the precise amino acid substitution and its effect on domain function. Variants disrupting the FHA domain may abolish substrate recognition, while those in the kinase domain can impair catalytic activity or prevent activation-loop phosphorylation. The I157T missense variant, for instance, affects the FHA domain and shows reduced kinase activity in functional assays, though its clinical effect size appears smaller than that of truncating variants.
Variant interpretation for CHEK2 must account for population-specific allele frequencies, as some pathogenic variants show founder effects in particular ethnic groups. Clinical laboratories assess variants using evidence from segregation studies, case-control comparisons, functional assays measuring kinase activity and substrate phosphorylation, and computational predictions of structural impact. Because CHEK2 functions as a tumour suppressor, loss-of-function is the primary pathogenic mechanism, but dominant-negative effects have been proposed for certain variants that might interfere with wild-type protein function in heterozygous carriers.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.909-?_1095+?del | - | Pathogenic | ★★☆☆ | Familial cancer of breast |
c.100_101del | p.Gln34fs | Pathogenic/Likely pathogenic | ★★☆☆ | Breast and/or ovarian cancer |
c.1006C>T | p.Gln336Ter | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.1007del | p.Gln336fs | Pathogenic | ★★☆☆ | not provided |
c.100C>T | p.Gln34Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Familial cancer of breast |
c.1011C>A | p.Tyr337Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Hereditary cancer-predisposing syndrome |
c.1018G>T | p.Glu340Ter | Pathogenic | ★★☆☆ | Familial cancer of breast |
c.1022del | p.Asn341fs | Pathogenic | ★★☆☆ | Familial cancer of breast |
c.1025del | p.Gly342fs | Pathogenic/Likely pathogenic | ★★☆☆ | Hereditary cancer-predisposing syndrome |
c.1030del | p.Ile344fs | Pathogenic/Likely pathogenic | ★★☆☆ | Familial cancer of breast |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic CHEK2 variants are associated with an autosomal dominant cancer predisposition syndrome characterised by moderately increased risk for multiple tumour types. The most extensively documented association is with hereditary breast cancer: female carriers face a two- to threefold increased lifetime risk compared to the general population, though individual risk varies considerably. The magnitude of risk depends on variant type, with protein-truncating variants generally conferring higher risk than missense changes, and on family history, with higher absolute risks observed in individuals with affected first-degree relatives.
Beyond breast cancer, evidence supports elevated risk for prostate cancer in male carriers, with some studies suggesting a two- to threefold increase. Colorectal cancer risk also appears elevated, as do risks for kidney and thyroid malignancies, though effect sizes for these latter associations are less precisely quantified. The syndrome does not include the very high ovarian cancer risk seen with BRCA1 or BRCA2 pathogenic variants, an important distinction for genetic counselling and risk management planning.
Inheritance pattern
Conditions caused by pathogenic CHEK2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the NHS Genomic Medicine Service, CHEK2 appears on multiple PanelApp gene panels that define clinically relevant genetic testing in the UK. The gene holds green (high evidence) classification on the Familial Breast Cancer panel, reflecting strong evidence for its role in breast cancer predisposition and supporting its inclusion in testing for individuals with suggestive personal or family history. It also has green status with specific indications on the Inherited Breast Cancer and Ovarian Cancer panel (NHS test code R208) and the Inherited Prostate Cancer panel (NHS test code R430).
These PanelApp classifications guide when CHEK2 sequencing is appropriate within NHS diagnostic pathways. For breast cancer, testing may be offered to individuals with early-onset disease, bilateral disease, or a family history suggestive of inherited predisposition, particularly when BRCA1/2 testing has been negative or is being conducted as part of a multi-gene panel. For prostate cancer, CHEK2 testing is considered in the context of early onset, aggressive histology, or clustering of prostate or breast cancers in the family. The green ratings indicate that variants identified in CHEK2 are reported as clinically relevant findings, informing subsequent surveillance and management recommendations.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
It is important to note that most lifestyle evidence comes from general population studies, as specific research in CHEK2 carriers remains limited. For individuals with pathogenic CHEK2 variants, lifestyle considerations centre on risk-reduction strategies supported by general population evidence, though no intervention can eliminate inherited cancer risk entirely. Maintaining a healthy body weight throughout adulthood is associated with reduced breast cancer risk in large epidemiological studies, and this association may be particularly relevant for CHEK2 carriers, given that adiposity-related hormonal changes can promote tumourigenesis in susceptible individuals. Regular physical activity, particularly moderate to vigorous exercise sustained over time, has shown protective associations with both breast and colorectal cancer in population-level research.
Alcohol consumption presents a modifiable risk factor, as ethanol and its metabolites have established links to breast cancer development through multiple mechanisms, including effects on oestrogen metabolism and DNA damage. Evidence suggests that even moderate consumption elevates risk, and individuals with genetic predisposition may wish to discuss alcohol intake with their healthcare providers as part of a comprehensive risk-management plan. For colorectal cancer, dietary patterns rich in fibre from whole grains, vegetables and legumes, combined with limited red and processed meat consumption, align with protective associations observed in prospective cohort studies.
Smoking avoidance is relevant across cancer types, though the association between smoking and breast cancer is more evident for long-term or heavy exposure. For CHEK2 carriers with prostate cancer risk, emerging evidence suggests that dietary patterns emphasising plant-based foods, omega-3 fatty acids from fish, and lycopene-rich tomatoes may offer modest protective effects, though data remain inconclusive. Any lifestyle modifications should be undertaken as part of a personalised discussion with a healthcare professional familiar with the individual's complete risk profile and medical history.
Supplement considerations
The evidence base for nutritional supplements in cancer prevention among CHEK2 variant carriers remains limited and largely extrapolated from general population studies. Vitamin D has attracted substantial research interest given its role in cellular differentiation and immune function, and some observational studies have suggested inverse associations between circulating vitamin D levels and breast or colorectal cancer risk. However, randomised controlled trials have not consistently demonstrated that vitamin D supplementation reduces cancer incidence, and optimal dosing remains uncertain. Individuals considering vitamin D supplementation should discuss appropriate doses and monitoring with a healthcare provider, particularly as excessive intake can cause toxicity.
Calcium supplementation, often studied alongside vitamin D, has shown mixed results for colorectal cancer prevention in clinical trials, with modest risk reductions observed in some but not all analyses. There is no conclusive evidence that calcium supplementation prevents breast or prostate cancer. High-dose antioxidant supplements such as beta-carotene and vitamin E have not demonstrated protective effects in rigorous trials and, in some studies, have been associated with increased cancer risk in certain subgroups, highlighting the importance of caution with high-dose supplementation.
Omega-3 fatty acid supplements derived from fish oil have been investigated for cancer prevention, but trial evidence does not support a clear protective effect for breast, prostate, or colorectal malignancies. Folate supplementation may influence colorectal cancer risk through effects on DNA methylation and synthesis, though the relationship appears complex, with both deficiency and excessive intake potentially affecting tumourigenesis. No supplement has been shown to eliminate or substantially reduce cancer risk in individuals with genetic predisposition, and any supplementation should be discussed with a healthcare professional in the context of the individual's overall nutritional status, medical history, and prescribed medications to avoid interactions or adverse effects.
Frequently asked questions
What cancers are associated with CHEK2 variants?
Pathogenic CHEK2 variants are most strongly associated with breast cancer, conferring approximately two- to threefold increased lifetime risk in female carriers. Evidence also supports elevated risk for prostate cancer, colorectal cancer, kidney cancer and thyroid cancer, though effect sizes vary by variant type and family history.
How does CHEK2 differ from BRCA1 and BRCA2?
While all three genes encode proteins involved in DNA damage response and repair, BRCA1 and BRCA2 pathogenic variants typically confer higher breast and ovarian cancer risks than CHEK2 variants. CHEK2 variants are not strongly associated with ovarian cancer, and the magnitude of breast cancer risk is generally lower than that seen with BRCA1/2, though still clinically significant.
Is CHEK2 testing available on the NHS?
CHEK2 is included on several NHS PanelApp gene panels with green (high evidence) status, including those for familial breast cancer and inherited prostate cancer. Testing is offered through NHS Genomic Medicine Services to individuals meeting clinical criteria based on personal or family history of relevant cancers.
Do all CHEK2 variants cause the same level of cancer risk?
No, cancer risk varies by variant type and location within the gene. Protein-truncating variants, such as the c.1100delC frameshift alteration, generally confer higher risk than most missense variants. Individual risk also depends on family history and other personal factors, making genetic counselling important for interpreting results.
What screening is recommended for CHEK2 variant carriers?
Surveillance recommendations are individualised based on the specific variant, personal and family cancer history, and other risk factors. For breast cancer, this may include earlier or more frequent mammography and consideration of MRI screening. Prostate cancer surveillance may involve PSA testing and digital rectal examination. Recommendations should be discussed with a clinical genetics service or oncology specialist.
Can CHEK2 variants be inherited from either parent?
Yes, CHEK2 variants follow an autosomal dominant inheritance pattern, meaning a variant can be inherited from either mother or father. Each child of a carrier has a 50% chance of inheriting the variant. Some carriers have no family history of cancer due to variable penetrance or because the variant arose de novo.